Olesya Zavoloka1, Pavlo Bezditko2, Irina Lahorzhevska2, Darya Zubkova2, Yevgeniya Ilyina2. 1. Department of Ophthalmology, Kharkiv National Medical University, 4 Lenina av., Kharkiv, Ukraine. olesya_zavoloka@mail.ru. 2. Department of Ophthalmology, Kharkiv National Medical University, 4 Lenina av., Kharkiv, Ukraine.
Abstract
BACKGROUND: Although the majority of cases of acute central serous chorioretinopathy are self-limited, resolving spontaneously after a number of weeks, the recurrence rate is estimated to be 20-50 %, and some cases will be chronic, lasting 6 months or longer. The evidence of Helicobacter pylori infection appears more often in patients with central serous chorioretinopathy. The purpose of this work was to estimate the efficiency of H. pylori infection eradication in treatment of patients with acute central serous chorioretinopathy. METHODS:Ninety-three patients with acute central serous chorioretinopathy participated in this study. Patients were divided into an experimental group (33 Helicobacter pylori-positive patients who received eradication treatment) and two control groups who did not receive eradication treatment: 29 H. pylori-positive patients and 31 H. pylori-negative patients. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, fluorescein angiography. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, static perimetry, and Amsler grid. The follow-up period was 2 years. RESULTS:Helicobacter pylori eradication caused a decrease of disease duration at 3 months (p = 0.04) and recurrence frequency of 45.6 % (p = 0.03) as well as improvement of distant prognosis. After 2 years, visual acuity increased from 0.91 ± 0.07 to 0.99 ± 0.02 (p = 0.01), scotoma frequency decreased from 100 % eyes to 27.2 % (p = 0.001), and metamorphopsia frequency decreased from 57.6 % eyes to 39.4 % (p = 0.04). CONCLUSIONS:Helicobacter pylori eradication is effective in the treatment of H. pylori-positive patients with acute central serous chorioretinopathy.
RCT Entities:
BACKGROUND: Although the majority of cases of acute central serous chorioretinopathy are self-limited, resolving spontaneously after a number of weeks, the recurrence rate is estimated to be 20-50 %, and some cases will be chronic, lasting 6 months or longer. The evidence of Helicobacter pylori infection appears more often in patients with central serous chorioretinopathy. The purpose of this work was to estimate the efficiency of H. pylori infection eradication in treatment of patients with acute central serous chorioretinopathy. METHODS: Ninety-three patients with acute central serous chorioretinopathy participated in this study. Patients were divided into an experimental group (33 Helicobacter pylori-positive patients who received eradication treatment) and two control groups who did not receive eradication treatment: 29 H. pylori-positive patients and 31 H. pylori-negative patients. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, fluorescein angiography. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, static perimetry, and Amsler grid. The follow-up period was 2 years. RESULTS:Helicobacter pylori eradication caused a decrease of disease duration at 3 months (p = 0.04) and recurrence frequency of 45.6 % (p = 0.03) as well as improvement of distant prognosis. After 2 years, visual acuity increased from 0.91 ± 0.07 to 0.99 ± 0.02 (p = 0.01), scotoma frequency decreased from 100 % eyes to 27.2 % (p = 0.001), and metamorphopsia frequency decreased from 57.6 % eyes to 39.4 % (p = 0.04). CONCLUSIONS:Helicobacter pylori eradication is effective in the treatment of H. pylori-positive patients with acute central serous chorioretinopathy.
Entities:
Keywords:
Acute central serous chorioretinopathy; Helicobacter pylori eradication; Helicobacter pylori infection; Treatment of central serous chorioretinopathy
Authors: L Cotticelli; M Borrelli; A C D'Alessio; M Menzione; A Villani; G Piccolo; F Montella; M R Iovene; M Romano Journal: Eur J Ophthalmol Date: 2006 Mar-Apr Impact factor: 2.597
Authors: R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock Journal: Ophthalmology Date: 1996-12 Impact factor: 12.079
Authors: Jean Louis Georges; Hans J Rupprecht; Stefan Blankenberg; Odette Poirier; Christoph Bickel; Gerd Hafner; Viviane Nicaud; Jürgen Meyer; François Cambien; Laurence Tiret Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Antonietta Gerarda Gravina; Rocco Maurizio Zagari; Cristiana De Musis; Lorenzo Romano; Carmelina Loguercio; Marco Romano Journal: World J Gastroenterol Date: 2018-08-07 Impact factor: 5.742